LMAT Financials: Revenue Breakdown, Margins & Competitor Comparison
This article analyzes the financial performance of LeMaitre Vascular Inc (LMAT), focusing on its revenue breakdown, profitability margins, and competitor comparison. LMAT demonstrates strong profitability with a gross margin of 71.66%, operating margin of 29.22%, and net margin of 24.18%, along with a 15.80% Return on Equity. The article also benchmarks LMAT's gross margin against competitors VCYT and HAE, indicating its significant position in the sector.
LeMaitre Vascular (NASDAQ:LMAT) Upgraded at Freedom Capital
Freedom Capital upgraded LeMaitre Vascular (NASDAQ:LMAT) to a "hold" rating, contributing to a "Moderate Buy" consensus from analysts with an average price target of $105.80. The company recently exceeded quarterly earnings expectations, reporting $0.68 EPS and $64.45M in revenue, with revenue up 15.7% year-over-year. Despite recent insider selling, including CEO George W. LeMaitre selling 150,000 shares, insiders still retain a 9.5% ownership stake in the company.
SG Americas Securities LLC Raises Stock Position in LeMaitre Vascular, Inc. $LMAT
SG Americas Securities LLC significantly increased its stake in LeMaitre Vascular, Inc. by 343.7% in Q4 2025, adding 43,230 shares to hold a total of 55,809 shares valued at $4.53 million. This increase in institutional ownership comes despite substantial insider selling activities, with CEO George W. LeMaitre selling 150,000 shares and other insiders selling over 215,000 shares. LeMaitre Vascular also reported strong Q4 earnings, beating estimates with $0.68 EPS and $64.45 million in revenue, provided positive FY2026 guidance, and increased its quarterly dividend.
Is LeMaitre Vascular, Inc. (LMAT) a good stock to buy now?
This article evaluates whether LeMaitre Vascular, Inc. (LMAT) is a good investment opportunity. It likely delves into various financial metrics, market performance, and expert opinions to assess the stock's current prospects.
Dividend equivalents boost LeMaitre Vascular (LMAT) director stock awards
LeMaitre Vascular (LMAT) director John James O'Connor was awarded dividend equivalent rights linked to his existing stock awards on March 26, 2026. These rights, economically equivalent to common stock shares, accrued on previously granted restricted stock units and performance share units from 2023, 2024, and 2025 and will vest proportionally with those underlying awards. This transaction is considered a compensation-related accrual rather than open-market share activity.
LeMaitre (NASDAQ: LMAT) director receives dividend equivalent rights awards
LeMaitre (NASDAQ: LMAT) director Bridget A. Ross was granted dividend equivalent rights awards on March 26, 2026. These awards are tied to previously issued restricted stock unit and performance share unit awards from 2023, 2024, and 2025. The filing clarifies that these are routine equity compensation accruals and do not represent open-market trading.
LeMaitre (NASDAQ: LMAT) director awarded dividend equivalent rights
LeMaitre Vascular director Joseph P. Pellegrino Jr. reported multiple awards of dividend equivalent rights on March 26, 2026. These rights are tied to existing restricted stock unit and performance share unit awards granted between 2022 and 2025, and each right is the economic equivalent of one share of LeMaitre Vascular common stock. The transactions are compensation-related accruals and do not involve open-market purchases or sales.
LeMaitre Vascular (LMAT) director granted new dividend equivalent rights
LeMaitre Vascular director John A. Roush was granted dividend equivalent rights on March 26, 2026. These fractional awards, economically equivalent to one share of common stock each, are tied to previously granted restricted stock unit and performance share unit awards from 2023, 2024, and 2025. These are compensation-related accruals and not open-market stock transactions, vesting proportionately with the underlying equity awards.
[Form 4] LEMAITRE VASCULAR INC Insider Trading Activity
LeMaitre Vascular director Martha Shadan reported receiving equity-based compensation awards in the form of Dividend Equivalent Rights on March 26, 2026. These rights are linked to existing restricted stock unit and performance share unit awards granted between 2023 and 2025, and vest proportionately with the underlying stock awards. The filing indicates these are awards and not open-market purchases or sales of company stock.
LeMaitre Vascular (LMAT) president reports grants of dividend equivalent rights
LeMaitre Vascular's President and Director, David B. Roberts, reported receiving compensation-related grants of dividend equivalent rights on March 26, 2026. These rights are economically equivalent to common stock shares, accrue on previously granted restricted stock units and performance share units from various dates between 2022 and 2025, and vest proportionately with those underlying awards. This filing represents routine equity-based compensation accrual and does not involve open-market trading activity.
LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives Consensus Rating of "Moderate Buy" from Brokerages
Seven research firms have issued a "Moderate Buy" consensus rating for LeMaitre Vascular, Inc. (NASDAQ:LMAT), with an average 12-month price target of $105.80. The company recently exceeded quarterly earnings and revenue estimates and increased its quarterly dividend. However, insiders, including CEO George W. Lemaitre, have been net sellers of the stock.
Is LeMaitre Vascular, Inc. (LMAT) A Good Stock To Buy Now?
The article discusses a bullish thesis on LeMaitre Vascular, Inc. (LMAT), highlighting its evolution into a profitable global medical device company specializing in peripheral vascular surgery. Key factors include its portfolio of over 100 devices, a dedicated sales force, a serial acquisition strategy, and its fast-growing biologics platform. Financially, LMAT demonstrates disciplined growth with strong sales, operating income, and return on invested capital, making it a compelling long-term investment opportunity.
JPMorgan Chase & Co. Has $10.68 Million Position in LeMaitre Vascular, Inc. $LMAT
JPMorgan Chase & Co. reduced its stake in LeMaitre Vascular by 18.6% to 121,988 shares, now valued at $10.68 million, though institutional investors still hold about 84.6% of the stock. LeMaitre Vascular reported strong Q4 results, beating estimates with $0.68 EPS and $64.45 million in revenue, and subsequently raised its quarterly dividend and FY2026 EPS guidance. Despite significant insider selling totaling $23.1 million, including a large sale by CEO George W. LeMaitre, insiders still retain 9.5% ownership of the company.
LeMaitre Vascular Executive Stock Sale - March 2026 Update - News and Statistics
A senior executive at LeMaitre Vascular, Trent G. Kamke, Senior Vice President of Operations, sold 2,625 shares of company common stock for approximately $285,000 on March 11. This transaction, which involved the exercise and immediate sale of vested stock options, reduced his direct holdings by 28.22% to 6,677 shares. LeMaitre Vascular is a medical device manufacturer specializing in products for peripheral vascular disease.
LeMaitre Vascular Executive Stock Transaction Analysis
LeMaitre Vascular's Senior Vice President, Trent G. Kamke, sold 2,625 shares of common stock for approximately $285,000 on March 11, 2026, reducing his direct holdings by 28.22%. Despite this sale, the company demonstrated strong financial performance in Q4 2025 with a 16% sales increase and a 39% earnings rise, and projects continued growth for 2026. Analysts maintain a "Moderate Buy" rating for LMAT, with some raising price targets due to strong Q4 results and positive guidance.
A LeMaitre Vascular (LMAT) Insider Sold 2,625 Shares for $285K
Trent G Kamke, Senior Vice President of Operations at LeMaitre Vascular (LMAT), sold 2,625 shares of common stock for approximately $285,000 on March 11, 2026, following the exercise of vested options. This transaction reduced his direct equity exposure by 28.22% but is seen as a way for the executive to monetize equity given the company's strong performance, rather than a lack of confidence. LeMaitre Vascular reported significant sales and earnings growth in Q4 2025 and expects continued strong performance in the current year.
Vanguard disaggregates holdings; LMAT ownership shown as 0% (Vanguard)
The Vanguard Group filed an Amendment No. 6 to a Schedule 13G/A, reporting 0% beneficial ownership and 0 shares beneficially owned in LeMaitre Vascular Inc. This change follows an internal realignment on January 12, 2026, where certain Vanguard subsidiaries will now report their holdings separately. This disaggregation clarifies beneficial-ownership attribution due to reorganization rather than an active sale or transfer of securities.
69,202 Shares in LeMaitre Vascular, Inc. $LMAT Bought by Tudor Investment Corp ET AL
Tudor Investment Corp. ET AL recently acquired a new stake of 69,202 shares in LeMaitre Vascular, Inc. (NASDAQ: LMAT), worth approximately $6.06 million, increasing institutional ownership to 84.64%. The medical instruments supplier has received a "Moderate Buy" consensus rating from analysts, with an average price target of $105.80, and outperformed its latest quarterly earnings estimates. LeMaitre Vascular also announced an increase in its quarterly dividend to $0.25 per share.
LeMaitre Vascular (NASDAQ:LMAT) Stock Passes Above 200-Day Moving Average - What's Next?
LeMaitre Vascular's stock (NASDAQ:LMAT) recently surpassed its 200-day moving average, reaching $107.86. Analysts have a "Moderate Buy" consensus with an average target of $105.80, although several have raised their price objectives. The company exceeded quarterly earnings expectations, reported strong revenue growth, raised its dividend, and provided positive FY2026 guidance, despite significant insider stock sales.
LeMaitre Vascular, Inc. (LMAT): A bull case theory
This article presents a bullish investment case for LeMaitre Vascular, Inc. (LMAT). It would likely discuss the company's market position, financial health, growth opportunities, and why it is considered a good stock to buy. The analysis would aim to persuade investors of LMAT's potential for future appreciation.
Assessing LeMaitre Vascular (LMAT) Valuation After Strong Recent Share Price Momentum
LeMaitre Vascular (LMAT) has experienced strong recent share price momentum, with a 28% increase in the last month and 32.1% over the past three months, trading at $112.23. Despite this, its valuation is considered slightly overvalued at $112.23 compared to a fair value estimate of $111.00. The article suggests investors look into the underlying growth story, margin expansion, and potential risks like reliance on price increases and international approval challenges.
Assessing LeMaitre Vascular (LMAT) Valuation After Strong Recent Share Price Momentum
LeMaitre Vascular (LMAT) has seen strong share price momentum, with a 28% monthly return and 39.9% year-to-date return, bringing its stock to $112.23. Despite this, the company is considered 1.1% overvalued compared to a fair value estimate of $111.00, placing its underlying growth assumptions under close scrutiny. While double-digit organic top-line growth and margin expansion support bullish models, risks such as reliance on price increases and international approval challenges need to be monitored.
LeMaitre Vascular declares $0.20 dividend
LeMaitre Vascular has declared a quarterly dividend of $0.20 per share. This financial move provides a return to shareholders and reflects the company's capital allocation strategy.
LeMaitre Vascular (LMAT) president sells 3,311.68 shares in open market trade
LeMaitre Vascular's President and Director David B. Roberts sold 3,311.68 shares of the company's common stock on March 11, 2026. The open-market transaction occurred at a weighted average price of $107.6752 per share, with individual trades ranging from $106.52 to $108.65. Following this sale, Roberts directly holds 14,667.32 shares of LMAT common stock.
LeMaitre Vascular (LMAT) SVP exercises options, sells 2,625 shares
LeMaitre Vascular Senior Vice President Trent G. Kamke recently exercised stock options for 2,625 shares at $35.48 per share and subsequently sold all 2,625 shares at $108.50 per share. Following these transactions, Kamke directly retains 6,677 shares of LeMaitre Vascular common stock. This activity is detailed in a Form 4 SEC filing dated March 13, 2026, indicating an exercise-and-sell strategy.
Insider Sell: David Roberts Sells Shares of LeMaitre Vascular In
David Roberts, President and Director of LeMaitre Vascular Inc (LMAT), sold 3,312 shares of the company on March 11, 2026. This transaction brings his total holdings to 14,667.32 shares. Over the past year, Roberts has sold a total of 22,591 shares, with no purchases. LeMaitre Vascular Inc's stock was trading at $107.68, and with a GF Value of $94.03, it is considered modestly overvalued.
Kennedy Capital Management LLC Has $18.89 Million Holdings in LeMaitre Vascular, Inc. $LMAT
Kennedy Capital Management LLC significantly increased its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 31.6%, holding shares valued at $18.89 million, despite recent insider selling. LeMaitre Vascular exceeded its quarterly earnings and revenue estimates and raised its quarterly dividend. The company's stock shows institutional ownership of 84.64%, with several analysts rating it a "Moderate Buy."
LMAT (NASDAQ) Form 144: Trent Kamke plans sale of 2,625 shares via option exercise
LMAT (Lemaître Vascular Inc.) has filed a Form 144 indicating Trent Kamke's plan to sell 2,625 shares of common stock, stemming from a stock option exercise on March 11, 2026. The filing also notes a previous sale by Kamke of 1,044 shares on February 27, 2026, for $115,142.76. The proposed sale of 2,625 shares has an aggregate market value of $284,812.50 and will be handled by Morgan Stanley Smith Barney LLC.
LeMaitre Vascular, Inc. (NASDAQ:LMAT) Announces Quarterly Dividend of $0.25
LeMaitre Vascular, Inc. (NASDAQ:LMAT) has announced a quarterly dividend of $0.25 per share, representing a 25% increase from its previous dividend. The medical instruments supplier will pay this dividend on March 26th to shareholders of record on March 12th, with an ex-dividend date of March 12th. The company has a history of increasing its dividend for 14 consecutive years and its dividend payout ratio is comfortably covered by earnings.
Stronger 2025 Results, Higher Dividend and Buyback Might Change The Case For Investing In LeMaitre Vascular (LMAT)
LeMaitre Vascular (LMAT) reported strong Q4 and full-year 2025 results, with sales of US$64.45 million and US$249.6 million respectively, and net income of US$15.58 million and US$57.73 million. The company announced an increased quarterly dividend of US$0.25 per share and a US$100 million share repurchase program, signaling management's confidence and a focus on increased shareholder returns. This, combined with upbeat 2026 guidance, could alter the investment narrative for the medical device company.
Stronger 2025 Results, Higher Dividend and Buyback Might Change The Case For Investing In LeMaitre Vascular (LMAT)
LeMaitre Vascular (LMAT) recently announced stronger Q4 and full-year 2025 results, along with an increased quarterly dividend and a new US$100 million share repurchase program. The company also issued upbeat 2026 guidance, indicating management's confidence and a focus on increased capital returns for shareholders. Despite the positive outlook, the stock is trading near its consensus fair value, suggesting expectations are already high and caution is warranted due to potential valuation risks.
LeMaitre Vascular Experiences Revision in Its Stock Evaluation Amid Competitive Market Dynamics
LeMaitre Vascular, Inc. has adjusted its valuation, now showing a P/E ratio of 45 and a high dividend yield of 79.50%. The company demonstrates strong financial performance with ROCE at 25.60% and ROE at 13.00%. A comparison with competitors in the Pharmaceuticals & Biotechnology sector reveals a mixed landscape for the company.
LeMaitre Vascular Stock Forms Golden Cross, Signals Bullish Breakout Ahead
LeMaitre Vascular, Inc. has experienced a "Golden Cross," where its short-term moving average crossed above its long-term moving average, signaling a potential bullish trend. Despite underperforming the S&P 500 over the past year, the stock has shown significant year-to-date gains of 32.42%. Technical indicators are mixed, with bullish momentum from Bollinger Bands but mildly bearish monthly MACD, suggesting a pivotal point for future trading strategies.
LeMaitre Vascular Hits Day High with 24.41% Surge in Stock Price
LeMaitre Vascular, a small-cap company in the Pharmaceuticals & Biotechnology sector, experienced a significant intraday surge of 24.41% in its stock price, reaching USD 115.33. This impressive performance is part of a broader trend, with the stock up 40.18% year-to-date and 121.66% over three years, significantly outperforming the S&P 500. The company also demonstrates strong financial health with a low debt-to-equity ratio and high institutional investor confidence.
LeMaitre Vascular Stock: Why Wall Street Sees $109 Mean Target
LeMaitre Vascular (LMAT) recently saw its stock trade at $106.41 after tripling its Artegraft total addressable market estimate to $30 million. The company reported a strong Q4 with sales beating consensus, a 47% surge in operating income, and an increased dividend, signaling a shift towards a biologics-driven compounder. Wall Street analysts maintain a "buy" or "outperform" rating with a mean price target of $109.22, while TIKR's valuation model suggests a higher intrinsic value of $151.00, implying significant undervaluation.
Lemaitre Vascular SVP Kamke sells $115k in LMAT stock
Trent G. Kamke, Senior Vice President of Operations at Lemaitre Vascular (NASDAQ:LMAT), sold 1,044 shares worth $115,142 on February 27, 2026, and an additional 93 shares for tax obligations on February 26, 2026. These sales occurred while the stock was trading near its 52-week high, with InvestingPro indicating that the stock appears overvalued. The company recently reported strong Q4 2025 earnings, surpassing analyst expectations, and received an increased price target from Citizens.
LeMaitre Vascular (LMAT) director gains new stock through awards
LeMaitre Vascular director Bridget A. Ross acquired additional company stock through equity awards. She received 476 shares from the partial vesting of a performance share unit award and 1 share from dividend equivalent rights on February 26, 2026. These transactions increased her direct holdings to 3,942 shares, as detailed in a recent SEC Form 4 filing.
LeMaitre Vascular (LMAT) director gains shares from PSU and dividend rights
LeMaitre Vascular director John James O'Connor acquired 476 shares of common stock and exercised one dividend equivalent right, converting it into an additional share. These transactions, not open-market trades, resulted from the partial vesting of a Performance Share Unit award granted in December 2024. Following these actions, his direct common stock holdings in LeMaitre Vascular (LMAT) increased to 62,827 shares.
LeMaitre Vascular (LMAT) Is Up 16.4% After Strong Earnings, Dividend Hike And New Buyback Plan – Has The Bull Case Changed?
LeMaitre Vascular (LMAT) recently reported strong Q4 and full-year 2025 results, offered optimistic 2026 guidance, increased its dividend, and announced a new share buyback program. These actions, combined with international growth from products like Artegraft, aim to enhance shareholder returns and organic expansion. While the new guidance tied to international growth and product adoption is positive, questions remain about the sustainability of recent pricing and volume trends.
LeMaitre Vascular (NASDAQ:LMAT) Insider Sells $115,142.76 in Stock
LeMaitre Vascular insider Trent Kamke sold 1,044 shares of the company's stock for $115,142.76, reducing his position by 13.52%. The company recently reported Q4 2025 earnings which beat estimates and increased its quarterly dividend to $0.25 per share. Analyst ratings for LMAT are mixed, with an average "Hold" rating and a target price of $105.80.
LeMaitre Vascular (LMAT)'s Technical Outlook is Bright After Key Golden Cross
LeMaitre Vascular (LMAT) recently experienced a "golden cross" event, indicating a potential bullish breakout as its 50-day simple moving average surpassed its 200-day simple moving average. The company's stock has gained 27.3% over the past four weeks and holds a #2 (Buy) on the Zacks Rank, supported by positive revisions to earnings estimates for the current quarter. Investors are advised to consider adding LMAT to their watchlists due to these strong technical and fundamental indicators.
LeMaitre Vascular (LMAT)'s Technical Outlook is Bright After Key Golden Cross
LeMaitre Vascular (LMAT) recently experienced a "golden cross" event, where its 50-day simple moving average crossed above its 200-day simple moving average, signaling a potential bullish breakout. The stock has gained 27.3% over the past four weeks and holds a Zacks Rank #2 (Buy), supported by positive earnings estimate revisions. Investors are advised to consider LMAT for their watchlists due to these strong technical and earnings indicators.
LeMaitre Vascular Links Strong 2025 Results To Higher Shareholder Returns
LeMaitre Vascular (NasdaqGM:LMAT) reported strong Q4 and full-year 2025 financial results, leading to a new US$100 million share repurchase program and a 25% dividend increase. The company's focus on medical devices for vascular surgeons positions it to benefit from demand for related procedures, and management has issued optimistic guidance for 2026. This move signals confidence in the company's business and cash generation, offering improved shareholder returns.
LMAT SEC Filings - Lemaitre Vasculr 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for investors to access Lemaitre Vascular, Inc. (LMAT) SEC filings, including annual 10-K reports, quarterly 10-Q reports, and 8-K material event forms. It details recent insider trading activities and proposed stock sales by various directors and the Chairman/CEO, revealing transactions such as option exercises and share disposals. The platform also offers AI-powered summaries to help users understand complex regulatory documents and track insider transactions more efficiently.
LeMaitre Vascular, Inc. (LMAT): A Bull Case Theory
This article summarizes a bullish thesis on LeMaitre Vascular, Inc. (LMAT), a leading owner-operator in the peripheral vascular device market. The company is highlighted for its durable competitive advantage, dual growth engines (organic and inorganic), strong financials, and founder-led management, suggesting it is a high-quality investment opportunity despite operating in a fragmented market.
LeMaitre to Participate at Upcoming Investor Conferences in March
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced its participation in five investor conferences in March 2026, including the Leerink Partners Global Healthcare Conference, Citizens Life Sciences Conference, Barclays Annual Global Healthcare Conference, KeyBanc Capital Markets Healthcare Forum, and the 38th Annual ROTH Conference. Management will present at some events and be available for one-on-one meetings at others. LeMaitre specializes in devices, implants, and services for peripheral vascular disease.
Five investor conferences spotlight LeMaitre in busy March
LeMaitre Vascular (Nasdaq: LMAT) announced that its management will participate in five investor conferences throughout March 2026. These engagements include presentations and one-on-one meetings at various healthcare-focused events such as the Leerink Partners Global Healthcare Conference and the Barclays Annual Global Healthcare Conference, both in Miami, and a virtual KeyBanc Capital Markets Healthcare Forum. The company specializes in devices and services for peripheral vascular disease.
[144] LEMAITRE VASCULAR INC SEC Filing
This article reports on a Form 144 SEC filing by Lemaitre Vascular Inc. (LMAT). The filing indicates a proposed sale of 8,464 shares of common stock with an aggregate market value of $962,272.00, acquired through a Restricted Stock Unit/Stock Option Exercise on December 2, 2023.
LeMaitre to Participate at Upcoming Investor Conferences in March
LeMaitre Vascular, Inc. (Nasdaq: LMAT) announced its participation in five investor conferences in March 2026. Management will present at the Leerink Partners Global Healthcare Conference and the Citizens Life Sciences Conference, and will also be available for meetings at other key events. The company specializes in devices and services for peripheral vascular disease.
LeMaitre to Participate at Upcoming Investor Conferences in March
LeMaitre Vascular, Inc. (Nasdaq: LMAT) announced its participation in five investor conferences throughout March 2026. Management will present at the Leerink Partners Global Healthcare Conference, Citizens Life Sciences Conference, and KeyBanc Capital Markets Healthcare Forum, and will be available for one-on-one meetings at the Barclays Annual Global Healthcare Conference and the 38th Annual ROTH Conference. The company specializes in devices and implants for peripheral vascular disease treatment.
